Reviews/Osteoporosis Fracture Prevention/Denosumab versus bisphosphonate fracture risk
Denosumab Therapy · ostfrac_05 · v1
The corpus asks whether denosumab prevents fractures about as well as bisphosphonates, and the answer is mixed. In the places where the comparison is drawn against the injectable bisphosphonate zoledronate, the two look alike [1], and one very large matched cohort found total and major fractures comparable overall [3]. But against the oral bisphosphonate alendronate, several large real-world studies found denosumab did better, not merely equal [1][2], and a study in dialysis patients also favoured denosumab [7]. Every one of these comparisons comes from registries or insurance records rather than a randomised trial that assigned patients to each drug and counted fractures, which [2] notes does not exist. Because patients were not randomised, sicker or higher-risk patients may have been steered toward one drug, which can distort the comparison. The panel therefore treated 'similar' as directionally reasonable but not firmly established.
Denosumab and zoledronate showed no difference in fracture risk reduction in a registry cohort [1], and a large propensity-matched national cohort found total and major osteoporotic fracture comparable between denosumab and bisphosphonates (HR 1.06, 95% CI 0.98-1.15; HR 1.13, 95% CI 0.97-1.32) [3]. Against alendronate specifically, denosumab was associated with lower vertebral and any-fracture risk [1] and reduced major osteoporotic, hip, and non-vertebral fractures by 39%, 36%, and 43% respectively [2]. In dialysis-dependent patients, denosumab lowered composite fracture risk by 45% versus oral bisphosphonates (risk ratio 0.55, 95% CI 0.28-0.93) [7]. All of this comparative fracture evidence is observational; the one head-to-head randomised trial measured bone mineral density, not fractures [4], and a population-referenced study [5] and a narrow refracture outcome [6] are only indirect. The contested point: The division is between 'comparable' and 'superior': denosumab looks equal to zoledronate [1] and comparable overall in one matched cohort [3], yet repeatedly outperforms oral bisphosphonates, especially alendronate [1][2] and in dialysis patients [7]. Whether 'similarly' is the right word depends on whether bisphosphonates are read as a class or split into oral versus injectable agents.
All 7 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Osteoporosis Fracture Prevention, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
No head-to-head RCT on fracture outcomes exists; [2] states this explicitly. Every comparative estimate is observational and open to confounding by indication and channelling of denosumab to higher-risk patients.
The corpus contradicts 'similarly' in one direction: [1], [2] and [7] find denosumab superior to oral bisphosphonates, not equal. An equivalence claim undercut by repeated superiority findings is imprecise, not confirmed.
Where it remains uncertain. Every comparison is observational with no head-to-head randomised fracture trial [2], and the consistent superiority over oral bisphosphonates [1][2][7] sits awkwardly against a claim of equivalence.
Aleatory
Several estimates carry wide confidence intervals, e.g. the dialysis composite fracture risk ratio 0.55 (95% CI 0.28-0.93) [7] and the hip-fracture HR 0.54 (0.29-0.98) [1], so random variation alone leaves the size of any difference unsettled.
Epistemic
Head-to-head randomised evidence on fracture outcomes is lacking [2]; the only randomised head-to-head comparison measured bone mineral density, not fractures [4].
The load-bearing papers from a corpus of 7, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Strongest direct support for comparable fracture effectiveness.
“Total fracture and osteoporotic major fracture, as the main outcomes of efficacy, were comparable in the denosumab and bisphosphonate group (HR 1.06, 95% CI, 0.98-1.15, P = .14; HR 1.13, 95% CI, 0.97-1.32, P = .12, respectively).”
Panel auditInternal validity: medium · scope of inference: Korean patients over 50 taking denosumab or bisphosphonate from 2018 to 2022.Key limitations: observational design · claims-based outcomes · residual confounding · unspecified follow-up length
Comparable subsequent-hip-fracture risk between denosumab and ibandronate in a hip-fracture population.
“Higher risk of a subsequent HF was observed in women on DMAB (SHR 1.77, 95% CI 1.08-2.91) and on iBP (SHR 1.81, 95% CI 1.35-2.41)”
Panel auditInternal validity: medium · scope of inference: Austrian patients aged 50+ who sustained a hip fracture between 2012 and 2017.Key limitations: no direct drug-vs-drug contrast · small denosumab subgroup · observational · survival rather than fracture primary focus
Supports equivalence specifically against zoledronate.
“denosumab was associated with significantly greater risk reduction than alendronate and ibandronate for vertebral fractures”
Panel auditInternal validity: medium · scope of inference: Osteoporosis patients (89% female, median age 69) in a real-world registry receiving denosumab, bisphosphonates or both sequentially.Key limitations: observational design · confounding by indication · registry data · result differs by specific bisphosphonate
Both drugs are compared to the untreated population rather than head-to-head, so the abstract does not report the denosumab-versus-bisphosphonate contrast the claim requires.
Panel auditInternal validity: medium · scope of inference: Norwegian women aged 50-89 (2005-2016), outcome first-time hip fracture.Key limitations: no direct drug-vs-drug contrast · observational · far fewer denosumab users · comparison against population baseline
4 of 7 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent observational datasets bear directly on the claim, but mixed direction (comparable vs superior) and the absence of any randomised fracture evidence keep confidence in genuine equivalence modest.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomised head-to-head fracture trial. Every comparative fracture estimate is observational and open to confounding [2], so true equivalence cannot be confirmed from this corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised controlled trial assigning osteoporosis patients to denosumab versus a specified bisphosphonate with incident clinical fractures as the primary endpoint.
Open question: Does denosumab prevent clinical fractures equivalently to bisphosphonates when patients are randomised? Why it is still open: The corpus contains no randomised trial on fracture outcomes; [2] states such evidence is lacking and [4] measured only bone mineral density.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19